Bifidobacterium adolescentis capable of improving physiological activity function of vitamin D and relieving osteoporosis and application of bifidobacterium adolescentis

Abstract

The invention relates to bifidobacterium adolescentis capable of improving the physiological activity function of vitamin D and relieving osteoporosis and application of the bifidobacterium adolescentis, and belongs to the technical field of microorganisms. The bifidobacterium adolescentis CCFM1447 has the effects of relieving bone calcium loss, maintaining bone health, repairing bone injury, increasing the number of osteoblasts and reducing the degree of osteoporosis, and has the specific effects that (1) the vitamin D metabolite level in the blood of a mouse with osteoporosis is remarkably improved; (2) the bone-related indexes of osteoporosis mice are obviously improved; and (3) the bone health of the osteoporosis mice is obviously improved, and the application prospect in preparation of the tablet for preventing and / or treating osteoporosis is huge.

Description

Technical Field

[0001] The invention relates to a strain of Bifidobacterium adolescentis capable of improving the physiological activity function of vitamin D and alleviating osteoporosis and application thereof, belonging to the technical field of microorganisms. Background Art

[0002] Osteoporosis is a systemic metabolic disease caused by various reasons, which leads to bone loss and reduction, changes in bone tissue microstructure, increased bone brittleness, and easily causes fractures in patients. Osteoporosis is divided into two categories: primary osteoporosis and secondary osteoporosis. Primary osteoporosis is further divided into two categories: senile osteoporosis and postmenopausal osteoporosis. Common symptoms of osteoporosis are pain, shortened stature, hunchback, fractures and decreased respiratory function. Calcium supplementation is the basic measure for the treatment of osteoporosis, but calcium supplementation alone is far from enough for the treatment of osteoporosis, and medications need to be added according to the patient's condition.

[0003] At present, bisphosphonates, selective estrogen receptor modulators, estrogen and calcitonin are mainly used to treat osteoporosis in clinic. These drugs can effectively promote the formation of osteoblasts and inhibit the formation of osteoclasts. However, bisphosphonates can cause severe bone, joint or muscle discomfort in some patients, and a small number of patients have an increased risk of jaw osteonecrosis when suffering from dental diseases or receiving invasive dental treatment; long-term use of alendronic acid is associated with the occurrence of subtrochanteric and femoral shaft fractures; selective estrogen receptor modulator raloxifene can increase the risk of venous thromboembolism and stroke; estrogen can increase the risk of endometrial hyperplasia and cancer in patients with intact uterus, and the incidence of gallstone disease and venous thromboembolism is also increased by 2 to 3 times; calcitonin may cause allergic reactions, severe patients may experience anaphylactic shock, and large-scale use of calcitonin can cause patients to have hypocalcemia, and some patients also experience joint pain and skeletal muscle pain. Therefore, it is urgent to find a drug or treatment method that can effectively relieve osteoporosis and will not cause complications and side effects in patients with long-term use.

[0004] Vitamin D (VD) is an important element for maintaining bone physiological function and bone growth and development. It plays an important role in bone calcium absorption. It can absorb calcium from the intestine into the blood and improve calcium absorption. It can also help guide calcium from the blood to the bones, so that calcium in osteoblasts will not be lost excessively, avoiding the occurrence of osteoporosis and bone growth and development disorders in children. Secondly, it can promote the formation of osteoblasts. The active form of VD, 1,25-dihydroxyvitamin D (1,25(OH)2D), can also act as a direct agonist and bind to the vitamin D receptor (VDR) for regulation in the human body. Appropriate supplementation of VD in children and the elderly will have direct benefits for bones, such as improving muscle strength and regulating the body's balance ability. It plays an important role in promoting human bone health.

[0005] Patients with osteoporosis often have reduced ability to metabolize vitamin D. Vitamin D is a fat-soluble vitamin that can be synthesized by the skin when exposed to ultraviolet light or taken in through the diet. Vitamin D needs to undergo two key metabolic steps in the body to work: first, the vitamin D synthesized in the skin is converted into 25-hydroxyvitamin D (25(OH)D), and then further converted into the active form 1,25(OH)2D in the kidneys. Patients with osteoporosis may have reduced ability to metabolize vitamin D for a variety of reasons. The most common reasons are aging and decreased renal function. With aging, the skin's ability to synthesize vitamin D decreases, resulting in a decrease in the level of 25(OH)D, the storage form of VD. At the same time, decreased renal function may hinder the production of 1,25(OH)2D, further reducing the ability to metabolize vitamin D. Therefore, the elderly and osteoporosis patients need to compensate for the reduced ability to synthesize VD by taking additional VD. However, simply taking VD is difficult to effectively solve the problem of reduced VD metabolism caused by osteoporosis, and it cannot completely relieve the symptoms of osteoporosis. Summary of the invention

[0006] In order to solve the above problems, the present invention screened out a strain of Bifidobacterium adolescentis CCFM1447. This Bifidobacterium adolescentis has the effect of improving the physiological activity of vitamin D and alleviating osteoporosis, which is specifically reflected in: (1) significantly improving the level of vitamin D metabolites in the blood of osteoporotic mice; (2) significantly improving the bone-related indicators of osteoporotic mice; (3) significantly improving the bone health of osteoporotic mice. Therefore, Bifidobacterium adolescentis has great application prospects in the preparation of products for improving the physiological activity of vitamin D, preventing and / or treating osteoporosis, and / or preventing and / or treating bone loss.

[0007] The technical solution of the present invention is as follows:

[0008] The present invention provides a strain of Bifidobacterium adolescentis CCFM1447, which has been deposited in the Guangdong Provincial Microbiological Culture Collection Center on October 31, 2024, with a collection number of GDMCC No: 65382, and a collection address of 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0009] In one embodiment of the present invention, the Bifidobacterium adolescentis

[0010] CCFM1447 was isolated from human feces. The 16S rRNA sequence of the strain was sequenced and analyzed as shown in SEQID NO.1. The sequence was compared in GenBank, and the results showed that the strain was Bifidobacterium adolescentis, and was named Bifidobacterium adolescentis CCFM1447.

[0011] In one embodiment of the present invention, the Bifidobacterium adolescentis

[0012] CCFM1447 is a Gram-positive bacillus that does not produce spores and is arranged singly, in pairs or in a V-shape. It is cultured anaerobically at 36°C on MRS (lactic acid bacteria culture medium) plates for 5 days and produces small colonies.

[0013] The invention provides a microbial preparation containing the Bifidobacterium adolescentis CCFM1447.

[0014] The invention provides a product containing the microbial preparation.

[0015] In one embodiment of the present invention, the product includes food, medicine or health care product.

[0016] In one embodiment of the present invention, the food comprises dairy products, soy products or fruit and vegetable products.

[0017] In one embodiment of the present invention, the product is prepared by fermentation using Bifidobacterium adolescentis CCFM1447 as a starter.

[0018] In one embodiment of the present invention, the method for preparing the starter is to inoculate Bifidobacterium adolescentis CCFM1447 into the culture medium at an inoculation amount of 5 to 8% of the total mass of the culture medium, and culture at 37°C for 18 hours to obtain a culture solution; centrifuge the culture solution to obtain bacterial cells; wash the bacterial cells 2 to 4 times with a phosphate buffer having a pH of 7.2, and then resuspend them with a lyophilization protective agent containing 100 g / L trehalose to obtain a resuspension; freeze-dry the resuspension by vacuum freezing to obtain Bifidobacterium adolescentis CCFM1447 powder; the mass ratio of the lyophilization protective agent to the bacterial cells is 2:1.

[0019] In one embodiment of the present invention, the culture medium comprises 87.7% water, 10% enzyme-hydrolyzed skim milk, 0.5% glucose, 1.5% tryptone and 0.3% dissolved yeast extract, accounting for 87.7% of the total mass of the culture medium.

[0020] In one embodiment of the present invention, the pH of the culture medium is 6.8.

[0021] The present invention provides the use of the above-mentioned Bifidobacterium adolescentis CCFM1447 in the preparation of medicines for preventing and / or treating osteoporosis.

[0022] In one embodiment of the present invention, the viable count of Bifidobacterium adolescentis CCFM1447 in the drug is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.

[0023] In one embodiment of the present invention, the medicine further contains a drug carrier and / or a pharmaceutical excipient.

[0024] The present invention provides the use of the Bifidobacterium adolescentis CCFM1447 in preparing a health product that helps to improve bone density.

[0025] In one embodiment of the present invention, in the health product, the viable count of Bifidobacterium adolescentis CCFM1447 is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.

[0026] Beneficial effects:

[0027] The present invention screened out a strain of Bifidobacterium adolescentis CCFM1447, which has the effect of improving the physiological activity of vitamin D and alleviating osteoporosis, which is specifically embodied in:

[0028] (1) Significantly increased total bone density, cortical bone density, distal femoral trabecular bone density, trabecular thickness, trabecular number, trabecular connectivity, bone surface area, bone volume, and bone volume fraction in osteoporotic mice;

[0029] (2) Significantly reduced trabecular separation in osteoporotic mice;

[0030] (3) Increase the levels of vitamin D metabolites 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the serum of osteoporotic mice;

[0031] (4) Reduce the levels of serum calcium and alkaline phosphatase in the serum of osteoporotic mice, and increase the levels of serum osteocalcin and type I procollagen amino-terminal propeptide.

[0032] Therefore, Bifidobacterium adolescentis CCFM1447 has great application prospects in the preparation of products (such as food, medicine or health care products, etc.) for preventing and / or treating osteoporosis.

[0033] Biomaterial Deposit

[0034] A strain of Bifidobacterium adolescentis CCFM1447, taxonomically named Bifidobacterium adolescentis, was deposited in the Guangdong Provincial Microbiological Culture Collection on October 31, 2024, with the collection number GDMCC No: 65382, and the collection address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 : The content of 25-hydroxyvitamin D in serum of osteoporotic mice in different groups;

[0036] Figure 2 : The content of 1,25-dihydroxyvitamin D in serum of osteoporotic mice in different groups;

[0037] Figure 3 : The serum calcium content in the serum of osteoporotic mice in different groups;

[0038] Figure 4 : The levels of alkaline phosphatase in serum of osteoporotic mice in different groups;

[0039] Figure 5 : The content of osteocalcin in serum of osteoporotic mice in different groups;

[0040] Figure 6 : The content of amino-terminal propeptide of type Ⅰ procollagen in serum of osteoporotic mice in different groups;

[0041] Figure 7 : Total bone density levels of osteoporotic mice in different groups;

[0042] Figure 8 :Cortical bone density levels in different groups of osteoporotic mice;

[0043] Fig. 9 :Bone mineral density of distal femur trabeculae in different groups of osteoporotic mice;

[0044] Fig.10 :The level of trabecular separation in different groups of osteoporotic mice;

[0045] Fig.11 :The trabecular thickness levels of osteoporotic mice in different groups;

[0046] Fig.12 :The number of trabecular bones in different groups of osteoporotic mice;

[0047] Fig.13 :The level of trabecular connectivity in different groups of osteoporotic mice;

[0048] Fig.14 :Bone surface area levels of osteoporotic mice in different groups;

[0049] Fig.15 :Bone volume levels of osteoporotic mice in different groups;

[0050] Fig.16 : Bone volume fraction levels in different groups of osteoporotic mice. DETAILED DESCRIPTION

[0051] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

[0052] The culture medium involved in the following examples is as follows:

[0053] MRS solid culture medium: peptone 10g / L, beef extract powder 5g / L, yeast extract powder 4g / L, glucose 20g / L, sodium acetate 5g / L, dipotassium hydrogen phosphate 2g / L, triammonium citrate 2g / L, magnesium sulfate 0.2g / L, manganese sulfate 0.05g / L, Tween 80 1g / L, agar 15g / L, cysteine ​​salt 0.5g / L, pH 6.8.

[0054] MRS liquid culture medium: peptone 10g / L, beef extract powder 5g / L, yeast extract powder 4g / L, glucose 20g / L, sodium acetate 5g / L, dipotassium hydrogen phosphate 2g / L, triammonium citrate 2g / L, magnesium sulfate 0.2g / L, manganese sulfate 0.05g / L, Tween 80 1g / L, cysteine ​​salt 0.5g / L, pH 6.8.

[0055] The detection methods involved in the following embodiments are as follows:

[0056] Detection method of viable bacteria count: adopt the national standard "GB 4789.35-2016 National Food Safety Standard Food Microbiology Detection Lactic Acid Bacteria Detection".

[0057] The present invention will be further described below in conjunction with specific embodiments.

[0058] Example 1: Screening and identification of Bifidobacterium adolescentis

[0059] 1. Screening

[0060] Human feces were used as samples. After pretreatment, the samples were stored in a -80°C refrigerator in about 20% glycerol. After being taken out and thawed, 0.5 mL of the sample was mixed and added to 4.5 mL. Gradient dilutions were performed with 0.9% saline containing 0.05% cysteine. Appropriate gradient dilutions were selected and spread on MRS plates with 0.05% cysteine. The plates were cultured at 37°C for 48 hours. Typical colonies were picked and streaked on MRS plates for purification. Single colonies were picked and transferred to liquid MRS culture medium (containing 0.05% cysteine) for bacterial growth and preserved in 30% glycerol to obtain strain CCFM1447.

[0061] 2. Identification

[0062] The genome of CCFM1447 was extracted, and the 16S rDNA of CCFM1447 was amplified and sequenced (Shanghai Sangon Biotechnology Co., Ltd.). The sequence was compared in GenBank, and the results showed that the strain was Bifidobacterium adolescentis, so it was named Bifidobacterium adolescentis CCFM1447.

[0063] Example 2: Cultivation of Bifidobacterium adolescentis

[0064] Bifidobacterium adolescentis CCFM1447 was inoculated into MRS solid culture medium (containing 0.05% cysteine) and cultured at 37°C for 48 hours. Its colonies were observed and its bacteria were observed under a microscope. It was found that it was a Gram-positive bacillus, did not produce spores, and was arranged singly, in pairs or in a V shape. The colonies were small and its bacteria were short rod-shaped and forked.

[0065] Bifidobacterium adolescentis CCFM1447 was inoculated into MRS liquid culture medium (containing 0.05% cysteine) and cultured at 37°C for 48 hours. A growth curve was drawn and it was found that it reached the stable phase after 12 hours of culture at 37°C.

[0066] Bifidobacterium adolescentis CCFM1447 was inoculated into MRS liquid culture medium (containing 0.05% cysteine) and cultured at 10, 15, 20, 25, 30, 35, 40, 45, and 50°C for 48 h, and then its growth was observed. It grew well at 20-35°C and still grew at 45°C, but hardly grew at 15°C or below or 50°C. It could survive when stored in 30% glycerol tubes at -80°C.

[0067] Bifidobacterium adolescentis CCFM1447 was inoculated into MRS liquid culture medium (containing 0.05% cysteine) and cultured at 37°C for 48 hours, then transferred to fresh MRS liquid culture medium (containing 0.05% cysteine) and cultured under the same conditions for 30 hours. The cells were centrifuged at 6000g for 15 minutes, washed with 0.9% saline and centrifuged again at 6000g for 10 minutes to obtain the cells, which were resuspended in 30% sucrose solution and frozen at -80°C for use.

[0068] Example 3: Effect of Bifidobacterium adolescentis on the levels of vitamin D metabolites in osteoporotic mice

[0069] 3-4 weeks old SPF grade C57BL / 6J male mice were divided into 3 groups, namely blank group (CON), model group (MOD), positive control group (VD) and intervention group (CCFM1447 experimental group), 8 mice in each group. The animals were raised in the Experimental Animal Center of Jiangnan University, fed with ordinary feed, with a constant temperature of 21-26℃, humidity of 40-70%, noise less than or equal to 60dB, and animal illumination of 15-20LX (all animal experimental procedures were reviewed and approved by the Animal Welfare and Ethics Management Committee of Jiangnan University).

[0070] The experimental period was 42 days in total. The model was established on the 7th day. Except for the blank group, the other mice were gavaged with 200 μL of 90 mg / kg BW / d retinoic acid once a day to induce osteoporosis for three weeks. After the model was established, the positive control group was gavaged with 200 μL of 0.06 μg / kg BW / d VD solution once a day, and the intervention group was gavaged with 0.2 mL of 1×10 viable bacteria once a day. 9 CFU / mL bacterial suspension, the blank group and the model group were only gavaged with an equal amount of sterile saline as a control, and all groups had free access to water and food for two weeks until the mice were killed on the 42nd day.

[0071] The experimental animal groups and treatment methods are shown in Table 1:

[0072] Table 1 Experimental animal groups

[0073]

[0074] After killing the mice, blood samples were collected and centrifuged to separate serum. The serum was tested using the Shanghai ELISA Mouse 25-hydroxyvitamin D ELISA Kit (ml038442) and Mouse 1,25-hydroxyvitamin D ELISA Kit (ml062981). Figure 1 , Figure 2 It can be seen that osteoporosis leads to a decrease in the level of vitamin D metabolites in the blood of mice; the positive control group significantly increased the level of vitamin D metabolites, and the levels of 25-hydroxyvitamin D and 1,25-hydroxyvitamin D increased by 42.27% and 27.90% respectively compared with the model group. The CCFM1447 experimental group significantly increased the level of vitamin D metabolites in osteoporotic mice compared with the model group, and the levels of metabolites 25-hydroxyvitamin D and 1,25-hydroxyvitamin D increased by 35.56% and 65.62% respectively compared with the model group.

[0075] The above experimental results show that Bifidobacterium adolescentis CCFM1447 can significantly increase the level of vitamin D metabolites in osteoporotic mice, and the effect is better than using VD treatment.

[0076] Example 4: Effect of Bifidobacterium adolescentis CCFM1447 on serum calcium levels in osteoporotic mice

[0077] The mouse grouping and modeling methods were the same as in Example 3.

[0078] On the 42nd day, the mice were killed, blood samples were taken, serum was separated by centrifugation, and serum calcium level was tested using Nanjing Jiancheng Serum Calcium Kit (C004-2-1). Figure 3 .

[0079] Depend on Figure 3 It can be seen that the serum calcium level of osteoporosis model mice was significantly higher than that of blank group mice. The positive control group reduced the serum calcium level by 18.02% compared with the model group. The serum calcium level of osteoporosis mice in the CCFM1447 experimental group was significantly reduced by 16.20% compared with the model group, reaching a level equivalent to that of the blank group, indicating that Bifidobacterium adolescentis CCFM1447 played a role in alleviating bone calcium loss, and the effect was equivalent to that of VD treatment.

[0080] Example 5: Effect of Bifidobacterium adolescentis CCFM1447 on serum alkaline phosphatase levels in osteoporotic mice

[0081] The mouse grouping and modeling methods were the same as in Example 3.

[0082] On the 42nd day, the mice were killed, blood samples were collected, serum was separated by centrifugation, and serum alkaline phosphatase levels were detected using Nanjing Jiancheng serum alkaline phosphatase kit (A059-2-2). Figure 4 .

[0083] Depend on Figure 4 It can be seen that the serum alkaline phosphatase level of osteoporosis model mice was significantly higher than that of normal mice. Compared with the model group, the serum alkaline phosphatase level of osteoporosis mice in the positive control group was significantly reduced, while the serum alkaline phosphatase level of osteoporosis mice in the CCFM1447 experimental group was reduced by 8.2%, reaching the same level as the control group, indicating that Bifidobacterium adolescentis CCFM1447 plays the same role as VD in maintaining bone health, repairing bone damage, and reducing the degree of osteoporosis.

[0084] Example 6: Effect of Bifidobacterium adolescentis CCFM1447 on serum osteocalcin levels in osteoporotic mice

[0085] The mouse grouping and modeling methods were the same as in Example 3.

[0086] On the 42nd day, the mice were killed, blood samples were collected, serum was separated by centrifugation, and osteocalcin levels were detected using the Elabscience Mouse Osteocalcin (OC / BGP) ELISA Kit (E-EL-M0864). Figure 5 .

[0087] Depend on Figure 5 It can be seen that the serum osteocalcin (OC) level of osteoporosis model mice was significantly lower than that of normal mice. Compared with the model group, the serum osteocalcin level of mice in the positive control group increased significantly by about 134.09%, while the serum osteocalcin level of osteoporosis mice in the CCFM1447 experimental group increased significantly by 216%, indicating that Bifidobacterium adolescentis CCFM1447 plays a role in enhancing osteoblast function, repairing bone damage and osteoporosis, and the therapeutic effect is better than VD.

[0088] Example 7: Effect of Bifidobacterium adolescentis CCFM1447 on the level of amino-terminal propeptide of type I procollagen in serum of osteoporotic mice

[0089] The mouse grouping and modeling methods were the same as in Example 3.

[0090] On the 42nd day, the mice were killed, and blood samples were collected from the mice. Serum was separated by centrifugation, and the serum level of type I procollagen amino-terminal propeptide (PⅠNP) was detected using the Elabscience mouse type I procollagen amino-terminal propeptide (PⅠNP) enzyme-linked immunosorbent assay kit (E-EL-M0233). The results are shown in Figure 6 .

[0091] Depend on Figure 6 It can be seen that the level of serum type I procollagen amino-terminal propeptide in osteoporosis model mice was significantly lower than that in the blank group mice. Compared with the model group, the serum PIPN level of mice in the positive control group increased significantly by about 51.53%, while the serum type I procollagen amino-terminal propeptide level of osteoporosis mice in the CCFM1447 experimental group increased significantly by 145.53%, indicating that Bifidobacterium adolescentis CCFM1447 plays a role in improving osteoblast synthesis, promoting new bone formation, repairing bone damage and osteoporosis, and the therapeutic effect is better than VD.

[0092] Example 8: Effects of Bifidobacterium adolescentis CCFM1447 on bone-related indicators in osteoporotic mice

[0093] The mouse grouping and modeling methods were the same as in Example 3.

[0094] The mice were killed on the 42nd day, and the femurs were taken for detection of bone-related indicators using Micro-CT. The observed parameters included total bone density (Bone Mean, BM), cortical bone density (Cortex Mean, CM), distal femoral trabecular bone density (Trabeculae Mean, TM), trabecular bone separation (trabecular bone separation, Tb.Sp), trabecular bone thickness (trabecular bone thickness, Tb.Th), trabecular bone number (trabecular bone number, Tb.N), trabecular connectivity (Conn.D), bone surface area (BS), bone volume (BV) and bone volume fraction (bone volume / totalvolume, BV / TV). The results are shown in Figure 7 to Figure 16 .

[0095] Depend on Figure 7 to Figure 16 It can be seen that compared with the blank group, the BM, TM, Tb.Th, Tb.N, Conn.D, BS, BV and BV / TV of the osteoporosis model group mice were significantly decreased, which were decreased by 3.1%, 5.27%, 10.61%, 25.64%, 42.60%, 22.33%, 23.93% and 18.18%, respectively, while Tb.Sp was significantly increased by 18.58%; after VD treatment, the BM, TM, Tb.Th, Tb.N and Conn.D of the positive control group were increased by 1.68%, 3.66%, 5.82%, 40.66% and 8.31% respectively compared with the model group, Tb.Sp was decreased by 20.77%, while BS, BV and BV / TV did not increase significantly. After oral administration of Bifidobacterium adolescentis CCFM1447, the BM, CM, TM, Tb.Th, Tb.N, Conn.D, BS, BV and BV / TV of mice were significantly increased, and compared with the model group, they increased by 5.69%, 6.94%, 4.03%, 12.35%, 15.69%, 83.96%, 22.38%, 35.51% and 42.04%, respectively, while Tb.Sp decreased significantly by 26.20%. It can be seen that Bifidobacterium adolescentis CCFM1447 can significantly increase the total bone density, cortical bone density, distal femoral trabecular bone density, trabecular thickness, trabecular number, trabecular connectivity, bone surface area, bone volume and bone volume fraction of osteoporotic mice, and at the same time, significantly reduce the trabecular separation of osteoporotic mice.

[0096] Compared with the positive control group, Bifidobacterium adolescentis CCFM1447 can significantly increase total bone density (increased by 1.04 times), cortical bone density (increased by 1.04 times), trabecular connectivity (increased by 1.70 times), bone surface area (increased by 1.29 times), bone volume (increased by 1.42 times), and bone volume fraction (increased by 1.47 times). These results indicate that Bifidobacterium adolescentis CCFM1447 intervention has the efficacy of treating osteoporosis, and the therapeutic effect is better than VD.

[0097] Example 9: Preparation of a product containing Bifidobacterium adolescentis CCFM1447

[0098] Bifidobacterium adolescentis CCFM1447 was used as the key ingredient, galacto-oligosaccharide and curcumin were added as prebiotics, and xylitol, maltodextrin and passion fruit juice powder were used as fillers. After mixing, sieving, homogenizing and drying, a 2g probiotic powder (with a viable count of not less than 1×10 6 CFU / g), and when using, just dissolve it in water and eat it.

[0099] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. A strain of Bifidobacterium adolescentis CCFM1447, characterized in that The Bifidobacterium adolescentis CCFM1447 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on October 31, 2024, with the collection number GDMCC No: 65382, and the collection address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

2. A microbial preparation containing the Bifidobacterium adolescentis CCFM1447 according to claim 1.

3. A product containing the microbial preparation according to claim 2.

4. The product according to claim 3, characterized in that The products include food, medicine or health products.

5. The product according to claim 4, characterized in that The food comprises dairy products, bean products or fruit and vegetable products.

6. Use of Bifidobacterium adolescentis CCFM1447 according to claim 1 in the preparation of medicines for preventing and / or treating osteoporosis.

7. The use according to claim 6, characterized in that In the medicine, the viable count of Bifidobacterium adolescentis CCFM1447 is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.

8. The use according to claim 7, characterized in that The medicine also contains a drug carrier and / or a pharmaceutical excipient.

9. Use of Bifidobacterium adolescentis CCFM1447 according to claim 1 in the preparation of a health product that helps to improve bone density.

10. The use according to claim 9, characterized in that In the health product, the viable count of Bifidobacterium adolescentis CCFM1447 is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.

Images